Mersana Therapeutics, Inc. Profile Avatar - Palmy Investing

Mersana Therapeutics, Inc.

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clin…

Biotechnology
US, Cambridge [HQ]

Balance Sheet

Loading...
End of MRSN's Analysis
CIK: 1442836 CUSIP: 59045L106 ISIN: US59045L1061 LEI: - UEI: -
Secondary Listings
MRSN has no secondary listings inside our databases.